A5039260055- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Antibiotic Use and Resistance
- Nail Diseases and Treatments
- Plant Pathogens and Fungal Diseases
- Contemporary Sociological Theory and Practice
- Bacterial Identification and Susceptibility Testing
- Antibiotic Resistance in Bacteria
- Antibiotics Pharmacokinetics and Efficacy
- Migration, Ethnicity, and Economy
- Neutropenia and Cancer Infections
- Infectious Diseases and Mycology
- Pneumocystis jirovecii pneumonia detection and treatment
- Pharmaceutical Economics and Policy
- Migration, Refugees, and Integration
- Migration and Labor Dynamics
- Race, History, and American Society
- Health Systems, Economic Evaluations, Quality of Life
- Social Policy and Reform Studies
- Labor Movements and Unions
- Mycotoxins in Agriculture and Food
- Antimicrobial Resistance in Staphylococcus
- Pharmaceutical studies and practices
- Political Economy and Marxism
- Clostridium difficile and Clostridium perfringens research
The University of Texas Health Science Center at Houston
2003-2024
Advanced Media Research (United States)
2024
Advent Life Sciences (United Kingdom)
2024
Wellesley College
2018-2020
St. Vincent's Birmingham
2020
Emmanuel College - Massachusetts
2020
RELX Group (Netherlands)
2020
AstraZeneca (United States)
2012-2017
University of Warwick
1992-2017
United Nations Industrial Development Organization
2017
Abstract Guidelines for the management of patients with invasive candidiasis and mucosal were prepared by an Expert Panel Infectious Diseases Society America. These updated guidelines replace previous published in 15 January 2004 issue Clinical are intended use health care providers who either have or at risk these infections. Since 2004, several new antifungal agents become available, studies been relating to treatment candidemia, other forms candidiasis, disease, including oropharyngeal...
During the past several decades, there has been a steady increase in frequency of opportunistic invasive fungal infections (IFIs) immunocompromised patients. However, is substantial controversy concerning optimal diagnostic criteria for these IFIs. Therefore, members European Organization Research and Treatment Cancer/Invasive Fungal Infections Cooperative Group National Institute Allergy Infectious Diseases Mycoses Study formed consensus committee to develop standard definitions IFIs...
Good evidence to support a recommendation against use Quality of 1 Evidence from у1 properly randomized, controlled trial 2 well-designed clinical trial, without randomization; cohort or case-controlled analytic studies (preferably 11 center); multiple time-series; dramatic results uncontrolled experiments 3 opinions respected authorities, based on experience, descriptive studies, reports expert committeesegies for these situations are discussed in the guidelines and must consider...
Amphotericin B has long been the standard treatment for candidemia, but its use is complicated by toxicity. More recently, fluconazole, a water-soluble triazole with activity against candida species and little toxicity, become available. We conducted multicenter randomized trial that compared amphotericin fluconazole as candidemia.
Infections due to Candida species are the most common of fungal infections. produce a broad range infections, ranging from nonlife-threatening mucocutaneous illnesses invasive process that may involve virtually any organ. Such infections requires an equally diagnostic and therapeutic strategies. This document summarizes current knowledge about treatment multiple forms candidiasis is guideline Infectious Diseases Society America (IDSA) for candidiasis. Throughout this document,...
We conducted a prospective, multicenter observational study of adults (n = 1447) and children 144) with candidemia at tertiary care centers in the United States parallel treatment trial that included nonneutropenic adults. Candida albicans was most common bloodstream isolate recovered from (45% vs. 49%) associated high mortality (47% among 29% children). Three-month survival better than (76% 54%; P < .001). Most received amphotericin B as initial therapy, whereas fluconazole. In adults,...
(See the Editorial Commentary by Clancy and Nguyen, on pages 1123–5.) Background. Invasive candidiasis (IC) is an important healthcare-related infection, with increasing incidence a crude mortality exceeding 50%. Numerous treatment options are available yet comparative studies have not identified optimal therapy. Methods. We conducted individual patient-level quantitative review of randomized trials for IC to assess impact host-, organism-, treatment-related factors clinical cure. Studies...
Measurement of (1-->3)-beta-D-Glucan (BG) has emerged as an adjunct diagnostic strategy for invasive fungal infections (IFI).Subjects at 6 clinical sites in the United States were enrolled either infection-negative subjects (n = 170) or with proven probable IFI according to European Organization Research and Treatment Cancer/Mycoses Study Group criteria 163). A central laboratory 4 performed assays. single sample was obtained per patient evaluated using assay detect serum BG derived from...
The Glucatell (1-->3)- beta-D-glucan (BG) detection assay (Associates of Cape Cod) was studied as a diagnostic adjunct for invasive fungal infections (IFIs). On the basis findings from preliminary study 30 candidemic subjects and healthy adults, serum BG level >or=60 pg/mL chosen cutoff. Testing performed with serial samples obtained 283 acute myeloid leukemia or myelodysplastic syndrome who were receiving antifungal prophylaxis. At least 1 sample positive at median 10 days before clinical...
ABSTRACT Candida bloodstream isolates ( n = 2,000) from two multicenter clinical trials carried out by the National Institute of Allergy and Infectious Diseases Mycoses Study Group between 1995 1999 were tested against amphotericin B (AMB), flucytosine (5FC), fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS), caspofungin (CFG), micafungin (MFG), anidulafungin (AFG) using NCCLS M27-A2 microdilution method. All drugs in NCCLS-specified RPMI 1640 medium except for...
A randomized, blinded, multicenter trial was conducted to compare fluconazole (800 mg per day) plus placebo with amphotericin B (AmB) deoxycholate (0.7 mg/kg day, the placebo/AmB component given only for first 5–6 days) as therapy candidemia due species other than Candida krusei in adults without neutropenia. total of 219 patients met criteria a modified intent-to-treat analysis. The groups were similar except that those who treated had higher mean (± standard error) Acute Physiology and...
When introduced in 1959, amphotericin B deoxycholate (AmBD) was clearly a life-saving drug. Randomized studies demonstrating its efficacy were not thought to be necessary, and it granted indications for many invasive fungal infections. Despite formidable toxicities, AmBD is thus often used as the primary comparator of Safer lipid-based versions (AmB) have been introduced, but difficulties with studying these agents generally led licensure salvage therapy, therapy. However, cumulative...